Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national, Randomized, Observer-blinded, Parallel Controlled Trial to Evaluate the Immunogenicity and Safety of New Generation COVID-19 mRNA Booster Vaccination Against Emerging Variants of Concern (VOC)

NCT05580159 is registered in ClinicalTrials.gov with Stemirna Therapeutics as lead sponsor.

NCT NCT05580159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05580159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national, Randomized, Observer-blinded, Parallel Controlled Trial to Evaluate the Immunogenicity and Safety of New Generation COVID-19 mRNA Booster Vaccination Against Emerging Variants of Concern (VOC)
Lead sponsor
Stemirna Therapeutics
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2022
Completion date
May 11, 2023
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, immunogenicity, safety